Singapore markets close in 2 hours 31 minutes
Straits Times Index
3,259.05 +33.88 (+1.05%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,771.23 +259.54 (+1.57%) FTSE 100
8,023.87 +128.02 (+1.62%) Bitcoin USD
66,656.70 +314.48 (+0.47%) CMC Crypto 200
1,403.01 -11.75 (-0.83%)
NeuBase Therapeutics, Inc. (NBSE)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.58M |
| Enterprise value | -5.66M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | N/A |
| Price/book (mrq) | 0.17 |
| Enterprise value/revenue | N/A |
| Enterprise value/EBITDA | 0.20 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.96 |
| 52-week change 3 | -84.01% |
| S&P500 52-week change 3 | 23.06% |
| 52-week high 3 | 4.8000 |
| 52-week low 3 | 0.3900 |
| 50-day moving average 3 | 0.6939 |
| 200-day moving average 3 | 0.8149 |
Share statistics
| Avg vol (3-month) 3 | 240.14k |
| Avg vol (10-day) 3 | 61.96k |
| Shares outstanding 5 | 3.75M |
| Implied shares outstanding 6 | 3.75M |
| Float 8 | 3.3M |
| % held by insiders 1 | 13.38% |
| % held by institutions 1 | 12.69% |
| Shares short (28 Mar 2024) 4 | 149.12k |
| Short ratio (28 Mar 2024) 4 | 0.6 |
| Short % of float (28 Mar 2024) 4 | 4.12% |
| Short % of shares outstanding (28 Mar 2024) 4 | 4.00% |
| Shares short (prior month 29 Feb 2024) 4 | 199.81k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 04 Feb 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:20 |
| Last split date 3 | 15 Jun 2023 |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Sept 2022 |
| Most-recent quarter (mrq) | 30 Sept 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -43.03% |
| Return on equity (ttm) | -93.46% |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -23.41M |
| Net income avi to common (ttm) | -24.59M |
| Diluted EPS (ttm) | -18.6000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 12.57M |
| Total cash per share (mrq) | 3.37 |
| Total debt (mrq) | 5.34M |
| Total debt/equity (mrq) | 58.39% |
| Current ratio (mrq) | 7.40 |
| Book value per share (mrq) | 2.45 |
Cash flow statement
| Operating cash flow (ttm) | -24.69M |
| Levered free cash flow (ttm) | -15.18M |
© 2024 Yahoo. All rights reserved.